YB new stock pitches (Fri, Aug 21)

Aurelion Research is adding Boston Scientific (BSX) as a new position to its 'Aurelion Index,' a high-quality medtech company trading at 12x earnings versus its ~20x historical average, following a special-situation selloff after its two growth engines—Farapulse (pulsed field ablation for irregular heartbeats) and Watchman (stroke-prevention heart plug for AFib), together ~25% of revenue—stalled in early 2026 due to increased competition (Abbott, J&J, Medtronic) and weaker demand from doctors overwhelmed by mixed clinical data, respectively; the story mirrors prior healthcare bets (MEDP, STVN, BRKR) of buying quality names facing short-term issues, with BSX historically compounding at 12.2% over 14 years via 7-8% organic growth, 1,220bps of margin expansion over 12 years (guided flat at 28% in 2026), and successful VC-style M&A (e.g., Farapulse acquired for ~$575M, Penumbra for $14.5B in Jan 2026). The bull case rests on three catalysts from an IR call: (1) management's conservative 2027 framework of 2-4% organic growth assumes a near worst-case scenario (other 75% grows ~6-7%, Watchman declines mid-to-high single digits, EP flat) and is viewed as a floor given BSX has cut guidance only twice in 15 years; (2) its first meaningful buyback since 2020 at $2B; (3) recurring, scheduled restructuring (2019, 2023, now) with savings landing in 2028. Additional positives include insider buying (CEO Michael Mahoney bought $9M on Aug 5, 2026—his largest purchase in years, +15% to his stake—plus two directors), a fixable urology segment (Axonics-related, growing 1%, targeting 6-7% market growth), continued Watchman investment signaling conviction, a large 2027-2028 pipeline (Farawave Ultra mid-2027, imaging and Faraflex in 2028; Watchman label expansion/Medicare decision possible in 2028 with 30-40% of eligible patients untreated), and China growth (>$1B revenue, APAC +12% in Q1 2026). Bear cases/risks include Farapulse potentially losing more US share than expected (one Abbott manager sees ~70% falling to 35-40% by 2027, hurt by weaker mapping until 2027), Watchman's problem being economic rather than just communication with a new competitor entering 2027 and no label/coverage change until 2028, and Penumbra pressuring margins/amortization and reducing balance-sheet flexibility. Free cash flow guidance was cut to ~$3.8B from ~$4B; the model assumes 8% earnings CAGR, ~62% EBITDA conversion (below management's high 70-80% target), EBITDA margins rising from 30.2% to 31.5% over 5 years, +0.7% share growth with excess cash to buybacks, and a re-rating to the bottom of its historical range (10-12x EBITDA). Aurelion sets a year-end 2026 price target of $67, declining to endorse the prior $100 target given uncertainty, arguing the risk/reward is attractive because the thesis works even if Farapulse and Watchman remain headwinds.

Read the full article here. Read time: 14 min

Suja Life ($SUJA), an organic beverage manufacturer whose stock has collapsed to ~$6.70 since its IPO despite improving fundamentals, trades at just 5.7x the midpoint of 2026 adjusted EBITDA guidance (~$403m EV, ~$259m equity on 38.6m economic shares), presenting a compelling five-year thesis. The company guides for $360-369m revenue and $70-72m adjusted EBITDA in 2026, with the IPO having repaid over $140m of debt (leaving ~$165m total debt, $20.6m cash, ~$19m annual interest). Suja operates two segments—mature Suja Core (Suja Organic + Vive Organic; $184.9m H1 2026 sales, $42.9m EBITDA, +25% YoY) and Emerging Brands (essentially Slice; $6.1m H1 revenue but losing $3.2m EBITDA, down from $9.5m in H1 2025). The base case assumes modest 9% revenue CAGR ($365m→$562m by 2031), EBITDA growing 12% ($71m→$125m) with margins rising 19.5%→22.2% as Slice reaches breakeven, manufacturing utilization improves, and fixed costs spread; it does not require Slice to become the next Celsius. Normalized 2026 FCF is ~$15m (EBITDA $71m less $19m interest, $6m cash taxes, $27m capex, $4m working capital), scaling to ~$68m by 2031 for ~$240m cumulative FCF (2027-2031); after ~$25m of assumed Tax Receivable Agreement payments (which pay pre-IPO owners 85% of tax savings, potentially $0-11.9m annually), ~$215m remains to eliminate debt and build cash to ~$70m by 2031. Assuming ~1% annual dilution (38.6m→40.6m shares) and a flat 6x exit multiple, the target is ~$20/share (3x return, ~25% IRR), with 8x yielding ~$26 and 10x yielding ~$33; most returns come from EBITDA growth, debt elimination, and cash accumulation rather than multiple expansion. Q2 gross margin was 46.7% (down from 47.4%), and capex is elevated (~$25-30m annually) for Oceanside capacity expansion. Key risks that would break the thesis include 29% customer concentration (one customer, with declining Nielsen-tracked velocity expected to persist into Q3), potential customer loss, structural gross margin deterioration, Slice continuing to consume cash, capex staying elevated, failed refinancing, poor acquisitions, and larger/earlier TRA payments.

Read the full article here. Read time: 9 min

Jumia Technologies ($JMIA), the only scaled listed e-commerce platform in Africa, trades at ~$6, and the author has bought the January 2028 $7/$15 call spread for a net $1.15 (bought $7 calls for $2.30, sold $15 calls for $1.15), offering ~7:1 (6X) potential payoff with $6.85 max profit, a $8.15 breakeven (stock up ~35%), and full value at $15—a level above the $14.72 52-week high from January and implying a $2.0 billion market cap on ~133 million post-raise ADSs. The bet is on an African e-commerce turnaround under CEO Francis Dufay (took over end of 2022), who cut cash burn from $285M (2023) to $107M, then $81M (2024) and $56M (2025), reduced headcount from ~4,300 to ~1,770, exited verticals and countries, and shifted toward a marketplace/fulfillment model with centralized pickup points across key African markets. Q2 results showed GMV of $216.3M (+23% ex-Algeria), gross profit $30.7M (+28%), 6.3M orders and 2.6M active customers (both +20%), and an adjusted EBITDA loss narrowing to $8.7M from $13.6M YoY, with strong growth in Nigeria (+36%), Ghana (+77%), and Egypt (+45%), though Ivory Coast (21% of physical goods GMV) fell 1% on cocoa price swings; quarterly losses have steadily declined ($15.7M Q1'25, $13.6M Q2'25, $10.7M Q1'26, $8.7M Q2'26). Management targets Q4 2026 breakeven on adjusted EBITDA/cash-flow and full-year 2027 adjusted EBITDA profitability (author personally models Q3 2027, structuring calls to allow until Q4 2027), and on August 11 raised $50M gross via 9.1M ADSs at $5.52, anchored by $25M from the IFC (a positive credibility signal), which the author believes funds them to breakeven despite the CEO claiming cash wasn't needed. Bull case: a breakeven Q4 and improving 2027 re-rate the stock as a functioning e-commerce business above $15, turning $1.15 into $8.00; bear/risk case: with over $2.2B cumulative losses, exposure to Middle East fuel prices, cocoa and global memory/chip costs, multiple currencies and economies, and unstable governments, the trade could go to zero—the author treats this as a case study within a diversified 'baker's dozen' of ~250-500 bps call spread positions rather than a YOLO.

Read the full article here. Read time: 6 min